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Abstract	
Telomere	 deregulation	 is	 a	 hallmark	 of	 cancer.	 Telomere	 length	 measured	 in	 lymphocytes	
(LTL)	 has	 been	 shown	 to	 be	 a	 risk	 marker	 for	 several	 cancers.	 For	 pancreatic	 ductal	
adenocarcinoma	 (PDAC)	 consensus	 is	 lacking	 whether	 risk	 is	 associated	 with	 long	 or	 short	
telomeres.	 Mendelian	 randomization	 approaches	 have	 shown	 that	 a	 score	 built	 from	 SNPs	
associated	with	LTL	could	be	used	as	a	robust	risk	marker.	We	explored	this	approach	 in	a	 large	
scale	study	within	the	PANcreatic	Disease	ReseArch	(PANDoRA)	consortium.	We	analyzed	10	SNPs	
(ZNF676-rs409627,	 TERT-rs2736100,	 CTC1-rs3027234,	 DHX35-rs6028466,	 PXK-rs6772228,	 NAF1-
rs7675998,	 ZNF208-rs8105767,	 OBFC1-rs9420907,	 ACYP2-rs11125529	 and	 TERC-rs10936599)	
alone	 and	 combined	 in	 a	 LTL	 genetic	 score	 (“teloscore”,	 which	 explains	 2.2%	 of	 the	 telomere	
variability)	 in	 relation	 to	 PDAC	 risk	 in	 2,374	 cases	 and	 4,326	 controls.	 We	 identified	 several	
associations	 with	 PDAC	 risk,	 among	 which	 the	 strongest	 were	 with	 the	 TERT-rs2736100	 SNP	
(OR=1.54;	 95%CI	 1.35-1.76;	 p=1.54x10-10)	 and	 a	 novel	 one	 with	 the	 NAF1-rs7675998	 SNP	
(OR=0.80;	95%CI	0.73-0.88;	p=1.87x10⁻⁶,	ptrend=3.27x10⁻⁷).	The	association	of	short	LTL,	measured	
by	 the	 teloscore,	with	 PDAC	 risk	 reached	 genome-wide	 significance	 (p=2.98x10-9	 for	 highest	 vs.	
lowest	quintile;	p=1.82x10-10	as	a	continuous	variable).	In	conclusion,	we	present	a	novel	genome-
wide	 candidate	SNP	 for	PDAC	 risk	 (TERT-rs2736100),	 a	 completely	new	signal	 (NAF1-rs7675998)	
approaching	genome-wide	significance	and	we	report	a	strong	association	between	the	teloscore	
and	risk	of	pancreatic	cancer,	suggesting	that	telomeres	are	a	potential	risk	factor	for	pancreatic	
cancer.		
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Novelty	and	Impact	Statement	
Telomere	length	measured	in	lymphocytes	(LTL)	is	a	risk	marker	for	several	cancer	types,	but	
for	pancreatic	cancer	the	association	is	unclear.	We	sought	to	clarify	this	point	with	a	large	scale	
association	 study	 using	 a	Mendelian	 randomization	 approach,	 i.e.	 with	 a	 “teloscore”	 built	 with	
genetic	polymorphisms	known	to	be	associated	with	LTL.	Low	teloscore	values	are	associated	with	
higher	risk	of	pancreatic	cancer.	
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Introduction	
Pancreatic	 cancer	 is	 a	 relatively	 rare	 disease,	 but	 it	 currently	 ranks	 as	 the	 fourth	 cause	 of	
cancer-related	deaths	in	Europe	and	USA,	and	is	projected	to	become	the	second	in	a	few	years.1	
There	are	several	established	or	suggested	environmental	risk	factors	for	pancreatic	cancer	such	
as	 smoking,	 heavy	 alcohol	 abuse	 and	 predisposing	 conditions	 like	 family	 history	 of	 pancreatic	
cancer,	 chronic	 pancreatitis,	 obesity,	 pre-existing	 diabetes	 mellitus.2,3	 In	 the	 last	 few	 years	
genome-wide	 associations	 studies	 (GWAS)	 and	 targeted	 large	 candidate	 gene/pathway	 studies	
have	identified	several	single	nucleotide	polymorphisms	(SNPs)	associated	with	pancreatic	cancer	
susceptibility	 and	 survival.4–18	 Among	 these	 reports	 several	 point	 towards	 a	 prominent	
involvement	of	the	TERT-CLPTM1L	gene	region	in	the	disease	etiology.5,7,10,15	This	region,	situated	
on	chromosome	5p15.33,	is	pleiotropic	and	there	are	overwhelming	epidemiologic	and	molecular	
evidences	on	 the	association	of	 SNPs	belonging	 to	 it	 and	 the	 risk	of	 various	 cancer	 types.19	 The	
pleiotropy	of	the	region	is	explained	by	the	central	role	that	TERT	exerts	in	the	cell.	The	TERT	gene	
encodes	 the	 telomerase	 reverse	 transcriptase,	 and	with	 the	 telomerase	 RNA	 component	 (TERC	
gene)	forms	a	key	part	of	the	telomerase	enzymatic	complex,	which	synthesizes	telomeric	ends.20	
Even	moderate	deregulations	of	 the	 telomerase	activity	 can	 jeopardize	 telomere	homeostasis21,	
which	 in	 turn	 can	 affect	 chromosomal	 stability,	 cell	 growth	 and	 the	 correct	 segregation	 of	
chromosomes	 to	 daughter	 cells.22,23	 Interestingly,	 considerable	 evidence	 from	molecular	 cancer	
biology	 indicates	 that	 telomere	 length	 in	 healthy	 or	 non-malignant	 tissues,	 usually	 studied	 as	
lymphocyte	 telomere	 length	 (LTL),	 also	 represents	 a	 risk	 marker	 for	 a	 large	 number	 of	 tumor	
types.	Telomere	 length	 is	highly	correlated	across	tissues24,25,	 therefore	LTL	 is	considered	a	valid	
surrogate	for	the	measure	of	telomere	length	in	specific	tissues.	For	pancreatic	cancer,	five	studies	
attempted	to	 link	LTL	with	risk	of	developing	the	disease.	The	results	were	contrasting	with	two	
studies	 reporting	 an	 association	 with	 shorter	 telomere	 length	 and	 increased	 risk5,26,	 one	 study	
reporting	 longer	 telomere	 and	 increased	 risk27	 and	 two	 studies	 reporting	 a	 U-shaped	
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association.28,29	 The	 lack	 of	 consensus	 for	 pancreatic	 cancer	 reflects	 the	 conflicting	 results	
reported	 for	 other	 cancer	 types	 and	 it	 is	 at	 least	 partially	 due	 to	 the	 techniques,	 particularly	
sensitive	 to	 sample	 handling30	 and	 other	 confounders31	 such	 as	 age,	 chemotherapy	 and	 the	
epidemiologic	design	of	the	study	(retrospective	vs.	prospective).32	The	associations	between	LTL	
and	various	types	of	cancer	and	the	possible	caveats	to	consider	have	been	reviewed	by	Hou	et	
al.31	However,	LTL	variability	is	under	genetic	control.	In	particular,	GWAS	have	identified	11	SNPs	
associated	with	LTL.	Recent	Mendelian	randomization	approaches	have	shown	that	a	score	built	
from	 these	SNPs	as	a	 surrogate	of	 LTL	 could	be	used	as	a	 robust	 risk	marker	 for	 several	 cancer	
types.33–38	Two	studies	attempted	this	for	pancreatic	cancer,	and	found	no	association.39,40	Given	
that	pancreatic	cancer	 is	a	rare	and	very	 lethal	disease,	 it	 is	crucial	to	expand	our	knowledge	on	
risk	 factors,	 by	 conducting	 a	 Mendelian	 randomization	 analysis	 of	 telomere	 length.	 This	 is	
potentially	a	better	way	than	measuring	LTL	directly,	given	the	difficulties	in	precisely	determining	
this	phenotype.	We	explored	 this	approach	 in	a	 large	 scale	 study	within	 the	PANcreatic	Disease	
ReseArch	 (PANDoRA)	 consortium,	 by	 analyzing	 10	 telomere-defining	 SNPs	 separately	 or	 in	
conjunction	computing	a	score.		
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Materials	and	methods	
For	 this	 study	 we	 used	 2,374	 pancreatic	 cancer	 cases	 and	 4,326	 controls	 belonging	 to	 the	
PANDoRA,	EPIC	and	ESTHER	consortia.	The	PANcreatic	Disease	ReseArch	 (PANDoRA)	consortium	
has	 been	 described	 in	 detail	 elsewhere.41	 We	 collected	 cases	 and	 controls	 from	 8	 European	
countries	 (Italy,	 Germany,	 Czech	 Republic,	 Hungary,	 United	 Kingdom,	 Lithuania,	 Poland,	
Netherlands).	Cases	were	defined	by	a	confirmed	diagnosis	of	PDAC	by	histopathology.	Controls	
were	 collected	 in	 the	 same	 geographical	 regions	 as	 the	 cases,	 mostly	 in	 the	 context	 of	 the	
PANDoRA	 consortium.	 Additionally,	 a	 part	 of	 the	 German	 controls	 was	 enrolled	 in	 ESTHER,	 a	
prospective	 cohort	with	 9,953	 participants	 recruited	 during	 a	 general	 health	 check-up	 between	
July	 2000	 and	 December	 2002	 in	 Saarland	 (a	 state	 in	 South-western	 Germany).	 The	 remaining	
German	controls	and	all	of	the	British	and	Dutch	controls	were	selected	from	healthy	volunteers	
recruited	from	the	general	population	in	the	European	Prospective	Investigation	on	Cancer	(EPIC),	
an	ongoing	prospective	cohort	 study	 in	 ten	European	countries	 (http://epic.iarc.fr/).	All	 subjects	
signed	 a	 written	 consent	 form.	 Ethical	 approval	 for	 the	 PANDoRA	 study	 protocol	 (that	 in	 this	
report	 also	 included	 controls	 from	 ESTHER	 and	 EPIC	 cohorts)	 was	 received	 from	 the	 Ethics	
Commission	of	the	Medical	Faculty	of	the	University	of	Heidelberg.	
	
SNP	selection	
We	selected	11	 independent	SNPs	(r2=0	for	all	pairwise	comparisons)	that	were	consistently	
shown	by	GWAS	to	influence	telomere	length.40	Our	final	selection	consisted	of:	ZNF676-rs409627,	
TERT-rs2736100,	 CTC1-rs3027234,	DHX35-rs6028466,	 PXK-rs6772228,	NAF1-rs7675998,	 ZNF208-
rs8105767,	 OBFC1-rs9420907,	 ACYP2-rs11125529,	 TERC-rs10936599	 and	 ZBTB46-rs755017.	 The	
polymorphic	variant	 reported	 in	 the	original	publication	 for	 the	ZNF676	gene	was	rs412658,	but	
the	 genotyping	 assay	 for	 this	 SNP	 failed	 quality	 controls,	 therefore	 we	 genotyped	 instead	
rs409627,	a	proxy	in	perfect	 linkage	disequilibrium	(r2=1	in	all	European	populations	of	the	1000	
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Genomes	project).	A	list	of	the	selected	SNPs	with	betas,	variance	explained	and	all	the	relevant	
information	can	be	found	in	table	1.	
	
Genotyping	
DNA	 was	 extracted	 from	 whole	 blood.	 Genotyping	 was	 carried	 out	 at	 the	 German	 Cancer	
Research	Center	 (DKFZ)	 in	Heidelberg,	Germany,	using	TaqMan	 (ABI,	Applied	Biosystems,	Foster	
City,	CA,	USA)	 technology.	Genotyping	was	conducted	 in	384	well	plates	and	 for	quality	control,	
duplicates	 of	 10%	 of	 the	 samples	 were	 interspersed	 throughout	 the	 plates.	 The	 order	 of	 DNA	
samples	from	case	and	control	subjects	was	randomized	on	plates	to	ensure	that	similar	numbers	
of	 cases	 and	 controls	 were	 analyzed	 in	 each	 batch.	 PCR	 plates	were	 read	 on	 a	 ViiA7	 real	 time	
instrument	(Applied	Biosystems).	The	ViiA7	RUO	Software,	version	1.2.2	(Applied	Biosystems)	was	
used	to	determine	genotypes.	
	
Teloscore	computation	
For	each	study	subject,	a	SNP	score	to	estimate	telomere	length	(which	we	called	“teloscore”)	
was	 computed	as	 follows:	 for	 each	SNP	 the	number	of	 alleles	 associated	with	 longer	 telomeres	
(according	 to	 the	 results	 of	 the	 literature	 reported	 in	 table	 1)	 were	 counted,	 and	 added	 up,	
resulting	 in	 the	 unweighted	 score	 for	 each	 subject.	 Since	 we	 finally	 selected	 10	 SNPs,	 the	
unweighted	score	can	assume	any	 integer	value	between	0	(shortest	telomeres)	and	20	(longest	
telomeres).	We	 then	 created	 a	weighted	 score	 for	 each	 study	 subject.	 First,	 we	 took	 from	 the	
literature	estimates	of	the	per-allele	effect	on	LTL	 in	base	pairs	for	each	SNP	(table	1).	Then,	we	
multiplied	at	each	SNP	 the	number	of	alleles	associated	with	 longer	 telomeres	by	 the	per-allele	
effect	on	 LTL	 in	base	pairs.	 Finally,	we	 summed	up	 these	quantities	 for	each	 study	 subject.	 The	
weighted	 score	 thus	 represents	 the	 estimated	 difference	 in	 telomere	 length,	measured	 in	 base	
pairs,	attributable	to	the	SNPs	under	investigation.	Only	a	subset	of	the	study	subjects	had	a	100%	
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SNP	 call	 rate	 (N=1246	 cases	 (52.5%),	 1945	 controls	 (45.0%),	 total	 3,191	 (47.6%)),	 while	 the	
remaining	 subjects	 had	 a	 call	 rate	 between	 80%	 and	 100%.	 Therefore,	 in	 order	 to	 be	 able	 to	
compute	 comparable	 score	 values	 for	 all	 study	 subjects,	we	 also	 considered	 average	 values	 for	
each	score.	Supplementary	table	1	shows	examples	of	how	the	teloscores	were	generated.	
	
Statistical	analysis	
The	 association	 between	 the	 SNPs	 and	 PDAC	 risk	 was	 tested	 using	 unconditional	 logistic	
regression	computing	odds	ratios	 (OR)	and	95%	confidence	 intervals	 (CI).	We	used	co-dominant,	
dominant,	recessive	and	per-allele	models	of	inheritance,	calculating	also	a	trend	test	for	the	co-
dominant	 model.	 The	 threshold	 for	 statistical	 significance	 was	 therefore	 p=0.05/(10	 SNPs	 x	 4	
models)=0.00125.	
We	used	each	of	 the	 teloscores	 (weighted	and	unweighted)	 as	 continuous	 variables	 and	as	
discrete	 values,	 calculating	quintiles	based	on	 the	distribution	of	 values	of	 the	healthy	 controls.	
The	 association	 between	 the	 teloscores	 and	 PDAC	 risk	 was	 tested	 with	 logistic	 regression,	
computing	ORs	and	95%	CIs.	
For	 a	 subset	 of	 German	 controls	 from	 the	 ESTHER	 cohort	 (N=885),	 Spearman’s	 correlation	
coefficients	 were	 calculated	 between	 the	 teloscores	 and	 values	 of	 relative	 telomere	 length	
previously	obtained	with	a	real-time	quantitative	PCR	protocol.42	
All	 analyses	were	adjusted	 for	age,	 sex	and	geographic	 region	of	origin.	Additional	 analyses	
were	 performed	 including,	 as	 adjustment	 factors,	 also	 tobacco	 smoking,	 diabetes	 diagnosed	 at	
least	two	years	before	onset	of	pancreatic	cancer	and	family	history	of	pancreatic	cancer,	which	
were	 available	 for	 subsets	 of	 cases	 and	 controls	 (supplementary	 table	 2).	 We	 also	 tested	 the	
association	between	the	teloscore	and	smoking	and	diabetes	as	endpoints.	Egger	regression	was	
used	 to	 test	 for	 possible	 pleiotropic	 effects	 of	 our	 genetic	 instrument.	 All	 statistical	 tests	were	
two-sided.	
	 12	
	
Bioinformatic	tools	
We	used	several	bioinformatic	tools	to	assess	possible	functional	relevance	for	the	three	SNPs	
showing	 the	 most	 significant	 associations	 with	 risk	 of	 pancreatic	 cancer.	 RegulomeDB	
(http://regulome.stanford.edu/)43	and	HaploReg44	were	used	 to	 identify	 the	 regulatory	potential	
of	 the	 region	 nearby	 each	 SNP.	 The	 GTEx	 portal	 web	 site	 was	 used	 to	 identify	 potential	
associations	between	the	SNP	and	expression	levels	of	nearby	genes	(eQTL).45	
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Results	
Data	filtering	and	quality	control	
Relevant	characteristics	of	the	study	population	are	shown	in	table	2.	All	the	genotyped	SNPs	
were	 in	 Hardy-Weinberg	 equilibrium	 when	 analyzed	 in	 controls	 with	 the	 exception	 of	 the	
polymorphic	 variant	 ZBTB46-rs755017	 that	 was	 therefore	 excluded	 from	 the	 statistical	 analysis	
and	from	the	score	computations.	Subjects	with	a	call	rate	lower	than	80%	(N=272	controls,	361	
cases,	total	633)	were	excluded	from	further	analyses.	This	left	2,374	cases	and	4,326	controls,	for	
whom	the	average	SNP	call	rate	was	95.7%,	with	a	minimum	of	81.81%	(ACYP2-rs11125529)	and	a	
maximum	 of	 98.99%	 (CTC1-rs3027234).	 Quality	 control	 analysis	 showed	 a	 concordance	 rate	 of	
98.85%.	
	
SNP	main	effects	
When	 analyzing	 the	 effect	 of	 the	 SNPs	 on	 PDAC	 risk	 we	 observed	 several	 statistically	
significant	 associations.	 The	 strongest	 from	 a	 statistical	 point	 of	 view	 was	 between	 the	
homozygous	 of	 the	 minor	 allele	 (A)	 compared	 with	 the	 carriers	 of	 the	 C	 allele	 of	 the	 TERT-
rs2736100	SNP	(OR=1.54;	95%CI	1.35-1.76;	p=1.54x10-10).	The	association	with	the	second	lowest	
p-value	was	between	carriers	of	the	minor	A	allele	of	the	NAF1-rs7675998	SNP	and	decreased	risk	
of	PDAC	 (OR=0.80;	95%CI	0.73-0.88;	p=1.87x10⁻⁶,	ptrend=3.27x10⁻⁷).	We	observed	 two	additional	
signals	that	were	very	close	to	the	threshold	for	multiple	testing,	both	assuming	a	recessive	model	
of	 inheritance:	 ZNF676-rs409627	 (OR=0.76;	 95%CI	 0.64-0.91;	 p=0.003)	 and	 ZNF208-rs8105767	
(OR=0.69;	95%CI	0.54-0.87;	p=0.002).	The	results	of	this	analysis	are	presented	in	table	3.	
	
Association	of	the	"teloscore"	with	telomere	length	measurement	and	PDAC	risk	
As	 a	 first	 step	we	 checked	whether	 the	 computed	 teloscore	was	 effectively	 able	 to	 predict	
telomere	 length.	 For	 this	 purpose	 we	 used	 part	 of	 the	 controls	 for	 which	 we	 had	 previously	
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measured	 telomere	 length	 with	 a	 real-time	 quantitative	 PCR	 protocol42	 and	 we	 observed	 a	
statistically	significant	association	between	the	teloscore	and	LTL	with	a	correlation	coefficient	of	
0.122	 (p=0.0017),	 confirming	 the	 hypothesized	 association	 between	 the	 genetic	 variance	 in	
telomeric	 genes	 and	 telomere	 length.	 In	 this	 subset	of	 controls	 the	10	 SNPs	 collectively	 explain	
3.35%	 of	 the	 telomere	 length	 variation.	 We	 subsequently	 tested	 the	 association	 between	 the	
score	and	PDAC	risk.	Since	not	all	the	individuals	were	genotyped	successfully	for	all	the	selected	
SNPs,	 in	 order	 to	 increase	 our	 statistical	 power	 we	 used	 the	 average	 scores	 rather	 than	 the	
absolute	values	 (see	methods).	Considering	 the	average	 score	we	observed	a	 strong	association	
between	 genetically	 determined	 long	 telomere	 and	decreased	 risk	 of	 PDAC	when	 analyzing	 the	
score	 as	 a	 categorical	 variable	 (OR=0.59;	 95%CI	 0.49-0.70;	 p=2.98x10-9	 for	 highest	 vs.	 lowest	
quintile)	and	also	as	a	continuous	variable	 (OR=0.88;	95%CI	0.85-0.92;	p=1.82x10-10).	The	results	
are	shown	in	table	4.	
We	checked	possible	associations	between	the	teloscore	and	known	risk	factors	for	pancreatic	
cancer,	 namely	 tobacco	 smoking	 and	diabetes	diagnosed	before	onset	of	 pancreatic	 cancer.	No	
association	was	 found.	Furthermore,	we	recalculated	the	association	between	the	teloscore	and	
pancreatic	 cancer	 risk	 by	 adding	 the	 risk	 factors	 as	 adjustment	 variables,	 but	 no	 substantial	
difference	was	observed	(data	not	shown).	
In	order	to	explore	the	possibility	that	some	of	the	SNPs	could	have	a	pleiotropic	association	
with	pancreatic	cancer	risk,	we	recalculated	the	teloscore	without	rs7675998	and	rs2736100,	that	
show	 the	 most	 significant	 associations	 with	 pancreatic	 cancer	 risk,	 and	 the	 results	 did	 not	
substantially	 change	 (data	 not	 shown).	 However	 Egger	 regression	 results	 were	 not	 statistically	
significant	(p=0.738).	
	
Possible	functional	effects	
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We	 used	 several	 bioinformatic	 tools	 to	 test	 for	 possible	 functional	 relevance	 for	 the	 four	
variants	 that	 reached	 study-wide	 significance	 (TERT-rs2736100,	 NAF1-rs7675998,	 ZNF676-
rs409627,	 ZNF208-rs8105767).	 RegulomeDB	 did	 not	 reveal	 any	 interesting	 regulatory	 potential	
associated	with	any	of	the	variants.	The	GTEx	portal	web	site,	 instead,	showed	that	all	the	SNPs,	
with	 the	exception	of	TERT-rs2736100,	are	multi-tissue	eQTLs	 (p<1.1	x10-4).	For	TERT-rs2736100	
there	 were	 no	 significant	 associations	 with	 gene	 expression	 levels	 in	 pancreatic	 tissue.	 It	 is	
interesting	to	note	that,	according	to	GTEx,	ZNF676-rs409627	modulates	the	expression	of	ZNF676	
in	the	pancreatic	tissue	(effect	size	0.59,	P=2.2	x	10-6).		
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Discussion	
There	 are	 overwhelming	 epidemiologic	 and	molecular	 evidences	 linking	 telomeres	with	 the	
etiology	of	 numerous	diseases.	However,	 given	 the	 capricious	nature	of	 association	 studies	 and	
the	 technical	 pitfalls	 in	 LTL	measurement,	 both	 short	 and	 long	 telomeres	 have	 been	 associated	
with	the	onset	of	multiple	cancer	types.	The	situation	is	particularly	unclear	for	pancreatic	cancer,	
with	 five	 published	 studies	 that	measured	 LTL	with	 a	 real-time	 quantitative	 PCR	 protocol.5,26–29	
Among	 these	 studies,	 four	 were	 conducted	 in	 prospective	 cohorts5,26,28,29	 and	 one	 in	 a	
retrospective	case-control	series27.	Two	studies	found	an	association	between	shorter	telomeres	
and	increased	risk	of	pancreatic	cancer,	one	found	an	association	with	longer	telomeres	and	two	
found	associations	with	both	longer	and	shorter	telomeres	(supplementary	table	3).	
Additionally,	two	studies	that	used	a	genetic	risk	score	reported	no	evidence	for	association	
with	pancreatic	cancer	risk.39,40	
The	aims	of	this	study	were	to	test	whether	telomere-related	SNPs	could	modulate	pancreatic	
cancer	risk,	and	to	use	genetic	markers	of	telomere	length	in	order	to	understand	whether	longer	
or	shorter	LTL	increase	the	risk	of	developing	PDAC.	
We	 observed	 a	 genome-wide	 significant	 association	 (p=1.54x10-10)	 between	 the	 TERT-
rs2736100	A	allele	and	increased	PDAC	risk.	This	SNP	is	pleiotropic	and	has	been	reported	to	be	
associated,	 alongside	 telomere	 length,	 with	 several	 cancer	 types.	 TERT-rs2736100	 has	 been	
reported	by	others5	and	by	ourselves7	 to	be	associated	with	PDAC	risk,	but	 this	 is	 the	 first	 time	
that	 the	association	reaches	a	genome-wide	 level	of	significance.	This	SNP	 is	 in	very	 low	 linkage	
disequilibrium	 with	 the	 other	 SNPs	 in	 this	 region	 that	 were	 reported	 to	 be	 associated	 with	
pancreatic	 cancer	 risk	 (rs401681	 r2=0.01,	 rs2736098	 r2=0.114)	 and	 therefore	 represents	 an	
independent	signal.	A	functional	explanation	for	the	consistent	associations	between	this	SNP	and	
cancer	risk	has	yet	to	be	found	however,	since	the	minor	allele	is	associated	both	with	increased	
PDAC	risk	and	with	decreased	LTL.	
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The	 association	 between	 NAF1-rs7675998	 SNP	 and	 decreased	 risk	 of	 PDAC	 is	 novel.	 The	
association	 is	 close	 to	 a	 genome-wide	 significance	 level	 (ptrend=3.27x10⁻⁷).	 The	 NAF1	 (nuclear	
assembly	factor	1)	gene product	is	part	of	a	complex	involved	in	the	assembly	of	telomerase46	and	
is	 therefore	 intimately	 linked	 to	 the	 telomerase	 activity	 and	 telomere	 length.	 According	 to	
HaploReg	NAF1-rs7675998	has	43	variants	in	high	LD	(r2>0.8)	and	41	of	them	(as	well	as	rs7675998	
itself)	are	predicted	to	alter	several	regulatory	motifs.	In	particular,	rs7675998	is	predicted	to	alter	
19	regulatory	motifs	including	those	of	the	forkhead	box	(FOX)	family.	According	to	GTEx	this	SNP	
has	 also	 two	eQTLs	 affecting	NAF1	 expression.	However,	 although	 these	 associations	 are	highly	
significant,	 they	 have	 not	 been	 observed	 in	 the	 pancreatic	 tissue.	 We	 observed	 two	 other	
potentially	interesting	associations	between	ZNF676-rs409627,	ZNF208-rs8105767	and	PDAC	risk.	
The	 role	 of	 these	 two	 genes	 in	 telomere	 maintenance	 has	 not	 been	 established	 yet	 although	
several	 hypotheses	 point	 to	 a	 possible	 involvement	 in	 stabilizing	 DNA	 or	 proteins	 that	 bind	 to	
DNA.47	According	to	GTEx,	rs409627	can	modify	ZNF676	expression	in	the	pancreatic	tissue	while	
rs8105767	can	modify	the	expression	of	ZNF208	in	various	tissues	but	not	in	pancreatic	cancer.	For	
both	 SNPs	 the	 allele	 associated	 with	 an	 increase	 in	 risk	 is	 the	 major	 allele,	 while	 the	 allele	
associated	with	 telomere	 shortening	 is	 the	minor	 one,	 indicating	 that	 possibly	 their	 association	
with	PDAC	risk	is	independent	from	telomere	length.	
The	 most	 important	 novel	 finding	 of	 this	 study	 is	 the	 statistically	 significant	 association	
between	genetically	determined	short	LTL	(assessed	through	the	teloscore)	and	increased	risk	of	
PDAC.	 The	 association	 reached	 genome-wide	 significance	 both	 considering	 the	 variable	 as	
categorical	(p=2.98x10-9	for	highest	vs.	lowest	quintile)	or	as	continuous	(p=1.82x10-10)	and	do	not	
support	a	U-shaped	association.	 It	 should	also	be	noted	as	a	proof	of	principle	 that	we	 found	a	
weak	 but	 significant	 correlation	 between	 the	 teloscore	 and	 LTL	 measured	 by	 an	 established	
method	 (real-time	quantitative	PCR)	 in	almost	900	controls	belonging	 to	our	dataset.	 In	 the	 last	
couple	 of	 years	 the	 approach	 of	 using	 SNPs	 related	 to	 telomere	 shortening	 as	 an	 instrumental	
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mean	to	 infer	 the	effect	of	 telomeres	on	cancer	etiology	has	been	successfully	used	 in	different	
tumor	 types	 such	 as	 B-cell	 lymphoma35,	 adult	 glioma36,	 breast	 cancer34	 and	 squamous	 cell	
carcinoma	 of	 the	 head	 and	 neck.48	 The	 use	 of	 genetic	 markers	 decreases	 the	 risk	 for	 reverse	
causation	 bias	 and	 therefore	 the	 differences	 in	 the	 studies	 (some	 finding	 association	 between	
cancer	risk	and	longer	telomeres,	some	with	shorter	telomeres)	may	reflect	tissue-specific	effects	
and	 activity	 of	 TL	 or	 a	 specific	 regulation	 of	 the	 genes	 involved	 in	 telomere	 regulation.	 It	 is	
interesting	 to	 note	 that	 TERT-rs2736100	 has	 been	 consistently	 associated	 with	 several	 cancer	
types	but	the	allele	increasing	the	risk	is	not	always	the	same.19	Given	the	strong	effect	of	genetic	
variants	on	LTL	and	given	that	the	allele	associated	with	telomere	shortening	is	always	the	same,	
the	difference	in	LTL	association	with	cancer	risk	may	be	explained	by	the	different	activity	of	the	
gene	in	different	tissues.		
Two	studies	previously	attempted	this	analysis	in	PDAC,	but	did	not	find	an	association.39,40	It	
is	difficult	to	speculate	about	the	reasons	for	the	discordance	with	our	results.	It	should	be	noticed	
that	 the	 results	 reported	 by	Haycock	 et	 al,	 based	 on	 the	 PanScan	GWAS	 (5105	 cases	 and	 8739	
controls),	 show	a	non-significant	 associations	between	 shorter	 telomeres	 and	pancreatic	 cancer	
risk	 (OR=0.86;	 95%CI	 0.56-1.32;	 p=0.50	 for	 PanSan	 and	OR=0.74,	 95%CI	 0.53-1.02,	 p=0.0657	 for	
PanC4),	which	are	compatible	with	our	results.40	The	results	of	the	other	study	do	not	show	any	
association	 between	 a	 teloscore	 of	 8	 LTL-associated	 SNPs	 and	 pancreatic	 cancer	 risk	 (OR=1.04;	
95%CI	0.97-1.12;	p=0.228),	although	the	sample	size	was	smaller	than	in	our	study	(1500	cases	and	
1500	controls).	Moreover,	their	score	was	calculated	in	a	different	way	from	ours	(i.e.	according	to	
a	dominant	model,	whereby	study	subjects	with	one	or	 two	copies	of	 the	allele	associated	with	
shorter	telomeres	were	combined	into	one	group	and	compared	with	those	who	carry	two	copies	
of	the	allele	associated	with	longer	telomeres).39	
Telomere	 shortening	 is	 known	 to	 be	 present	 in	 the	 first	 stage	 of	 pancreatic	 onset49	 and	 it	
could	be	an	important	determinant	of	cell	progression	to	malignant	state.5	Constitutionally	shorter	
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telomeres,	as	determined	by	germline	polymorphisms,	may	contribute	to	the	very	early	phases	of	
pre-malignant	transformation	of	pancreatic	cells.	
Our	study	has	several	obvious	advantages:	the	large	scale	and	the	ability	to	test	the	teloscore	
in	a	group	of	 individuals	for	which	telomere	 length	was	measured	by	RT-PCR	homogeneously,	 in	
the	 same	 laboratory,	 in	 samples	 collected	 from	 the	 same	 center	 (the	 controls	 belonging	 to	 the	
ESTHER	cohort	n=885)	and	using	exactly	the	same	procedure	for	sample	handling	and	storing.	A	
possible	 drawback	 is	 that	 we	 tested	 the	 teloscore	 on	 DNA	 collected	 from	 leukocytes	 and	 it	 is	
therefore	difficult	to	generalize	its	ability	to	be	used	as	a	proxy	for	other	tissues.	However,	there	is	
a	 growing	 literature	 suggesting	 that	 telomere	 shortening	 is	 generally	 consistent	 in	 different	
tissues50	and	that	the	variation	among	different	tissues	belonging	to	the	same	individual	is	lower	
that	 the	 variability	 between	 different	 individuals.49,51	 Additionally,	 an	 analysis	 with	 Egger	
regression	 did	 not	 yield	 a	 significant	 result,	 and	 pointed	 to	 high	 heterogeneity	 among	 SNPs,	
suggesting	a	possible	pleiotropic	effect	of	our	SNPs.	
In	 conclusion,	 here	we	present	 a	 novel	 genome-wide	 candidate	 for	 PDAC	 (TERT-rs2736100)	
and	 a	 completely	 new	 signal	 for	 PDAC	 in	 NAF1-rs7675998	 that	 approaches	 the	 genome-wide	
threshold.	In	addition,	we	found	a	strong	association	between	the	teloscore	and	risk	of	pancreatic	
cancer,	suggesting	that	telomeres	are	a	potential	risk	factor	for	pancreatic	cancer.		
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Table	1.	SNPs	associated	with	telomere	length	and	genotyped	in	this	studya.	
SNPs	 Chrb	 Posb	 Gene	 Alleles	(M/m)b	
Effect	
alleleb	 Beta
b	 SEb	 %	variance	explaineda	
Base	
pairsa	
rs409627c	 19	 22,176,638	 ZNF676	 G/C	 C	 0.086	 0.010	 0.484	 103.2	
rs2736100	 5	 1,286,401	 TERT	 C/A	 C	 0.085	 0.013	 0.310	 102.0	
rs3027234	 17	 8,232,774	 CTC1	 C/T	 C	 0.103	 0.012	 0.292	 123.6	
rs6028466	 20	 39,500,359	 DHX35	 G/A	 A	 0.058	 0.013	 0.041	 69.6	
rs6772228	 3	 58,390,292	 PXK	 T/A	 T	 0.041	 0.014	 0.200	 49.2	
rs7675998	 4	 163,086,668	 NAF1	 G/A	 G	 0.048	 0.012	 0.190	 57.6	
rs8105767	 19	 22,032,639	 ZNF208	 A/G	 G	 0.064	 0.011	 0.090	 76.8	
rs9420907	 10	 103,916,707	 OBFC1	 A/C	 C	 0.142	 0.014	 0.171	 170.4	
rs11125529	 2	 54,248,729	 ACYP2	 C/A	 A	 0.065	 0.012	 0.080	 78.0	
rs10936599	 3	 169,774,313	 TERC	 C/T	 C	 0.100	 0.011	 0.319	 120.0	
	
aData	from	refs.	52	and	40.	
bChr	 =	 chromosome;	 pos	 =	 base-pair	 position	 (GRCh38.p3);	 Effect	 allele	 =	 allele	 associated	 with	 longer	
telomeres;	Beta	=	standard	deviation	change	in	telomere	length	per	copy	of	the	effect	allele;	SE	=	standard	
error;	Base	pairs	=	telomere	length	difference	in	base	pairs	associated	with	each	allele.	
cSurrogate	of	rs412658	(r2=1).	
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Table	2.	Description	of	the	study	population.	
	 PDAC	cases	 Controls	
Country/region	 	 	
Germany	 789	 1,779	
Northern	Italy	 447	 540	
Central	Italy	 382	 535	
Southern	Italy	 103	 499	
Czech	Republic	 243	 156	
Poland	 74	 191	
Lithuania	 47	 172	
Netherlands	 106	 102	
Hungary	 95	 176	
United	Kingdom	 88	 176	
Total	 2,374	 4,326	
	 	 	
Sex	 	 	
Male	 1,342	 2,178	
Female	 1,008	 2,079	
	 	 	
Median	age	 65.6	 59.0	
(25th	–	75th	percentile)	 57.8-72.3	 49.7-66.0	
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Table	3.	Association	between	the	individual	SNPs	and	risk	of	developing	PDAC.	
Gene	 SNP	 Alleles	
(M/m)a	
MM	 Mm	 mm	 MM	vs.	Mm	 MM	vs.	mm	 Ptrend	 MM	vs.	Mm+mm	 Mm+MM	vs.	mm	 M	vs.	m	
OR	(95%CI)b	 Phet	 OR	(95%CI)	 Phom	 OR	(95%CI)	 Pdom	 OR	(95%CI)	 Prec	 OR	(95%CI)b	 P	
ZNF676	 rs409627c	 G/C	 710/1633	 803/1864	 230/616	 1.04	(0.91-1.19)	 0.563	 0.78	(0.64-0.95)	 0.011	 0.1552	 0.97	(0.86-1.10)	 0.656	 0.76	(0.64-0.91)	 0.003	 0.92	(0.84-1.01)	 0.071	
TERT	 rs2736100	 C/A	 598/1226	 983/1979	 581/818	 1.02	(0.89-1.17)	 0.778	 1.56	(1.34-1.83)	 2.60x10⁻⁸	 1.05x10⁻⁶	 1.17	(1.03-1.33)	 0.013	 1.54	(1.35-1.76)	 1.54x10⁻10	 1.24	(1.15-1.34)	 1.08x10-7	
CTC1	 rs3027234	 C/T	 1328/2521	 869/1528	 143/240	 1.09	(0.97-1.22)	 0.154	 1.09	(0.86-1.37)	 0.490	 0.1017	 1.09	(0.97-1.21)	 0.137	 1.05	(0.84-1.32)	 0.673	 1.06	(0.97-1.16)	 0.17	
DHX35	 rs6028466	 G/A	 2085/3687	 215/448	 18/24	 0.86	(0.72-1.04)	 0.118	 1.13	(0.59-2.16)	 0.716	 0.2118	 0.88	(0.73-1.05)	 0.156	 1.14	(0.60-2.19)	 0.684	 0.91	(0.77-1.07)	 0.233	
PXK	 rs6772228	 T/A	 2141/3738	 149/224	 6/12	 1.15	(0.91-1.46)	 0.242	 1.04	(0.37-2.95)	 0.935	 0.2545	 1.15	(0.91-1.45)	 0.247	 1.04	(0.37-2.93)	 0.948	 1.13	(0.91-1.40)	 0.273	
NAF1	 rs7675998	 G/A	 1451/2444	 753/1548	 102/284	 0.81	(0.72-0.92)	 0.001	 0.61	(0.48-0.79)	 1.18x10⁻⁴	 3.27x10⁻⁷	 0.78	(0.70-0.88)	 1.81x10⁻⁵	 0.66	(0.51-0.84)	 0.001	 0.80	(0.73-0.88)	 1.87x10-6	
ZNF208	 rs8105767	 A/G	 1197/1701	 912/1391	 200/343	 0.98	(0.85-1.12)	 0.719	 0.68	(0.53-0.87)	 0.002	 0.0391	 0.92	(0.80-1.04)	 0.184	 0.69	(0.54-0.87)	 0.002	 0.88	(0.80-0.98)	 0.018	
OBFC1	 rs9420907	 A/C	 1639/2992	 640/1174	 68/115	 0.99	(0.88-1.12)	 0.883	 1.16	(0.82-1.62)	 0.403	 0.8429	 1.00	(0.89-1.13)	 0.943	 1.16	(0.83-1.62)	 0.392	 1.02	(0.92-1.13)	 0.746	
ACYP2	 rs11125529	 C/A	 1732/2441	 474/719	 39/74	 1.04	(0.90-1.20)	 0.598	 0.85	(0.55-1.30)	 0.441	 0.0941	 1.02	(0.89-1.178)	 0.767	 0.84	(0.55-1.28)	 0.415	 1.00	(0.88-1.13)	 0.987	
TERC	 rs10936599	 C/T	 1372/2447	 782/1554	 134/275	 0.90	(0.80-1.01)	 0.081	 0.83	(0.66-1.05)	 0.117	 0.0365	 0.89	(0.80-1.00)	 0.040	 0.86	(0.69-1.09)	 0.208	 0.91	(0.83-0.99)	 0.032	
	
aM	=	major	allele;	m	=	minor	allele	
bOR	=	odds	ratio;	CI	=	confidence	interval.	All	analyses	were	adjusted	for	age,	sex	and	geographic	region	of	origin.	
cSurrogate	of	rs412658	(r2=1).	
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Table	4.	Association	between	teloscore	and	PDAC	risk.	
Scorea	 Controls	 Cases	 OR	 95%	CI	 Pvalue	
Quintile	1	(0-47.22)	 865	 580	 Ref.	 -	 -	
Quintile	2	(47.23-55.30)	 865	 555	 0.99	 (0.85-1.17)	 0.95	
Quintile	3	(55.31-61.80)	 866	 426	 0.74	 (0.63-0.88)	 5.30x10-4	
Quintile	4	(61.81-70.56)	 864	 469	 0.80	 (0.67-0.94)	 7.48x10-3	
Quintile	5	(70.57-112.05)	 866	 344	 0.59	 (0.49-0.70)	 2.98x10-9	
Continuous	variable	 4,326	 2,374	 0.88	 (0.85-0.92)	 1.82x10-10	
	
aWeighted	average	teloscore,	calculated	as	described	in	the	Methods	section	and	in	Supplementary	table	1.	
Quintiles	were	calculated	based	on	the	distribution	of	values	of	the	controls.	Numbers	in	parentheses	
represent	the	value	in	bp	that	define	the	boundaries	of	each	quintile.	All	analyses	were	adjusted	for	age,	
sex	and	geographic	region	of	origin.	The	unit	for	the	“continuous	variable”	is	the	increase	of	one	quintile.	
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Supplementary	table	1.	Examples	of	teloscore	computation.	
SNP	
Original	genotypes	 Unweighted	scorea	 Weighted	scoreb	
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Effect	alleleh	 C	 C	 C	 A	 T	 G	 G	 C	 A	 C	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Other	allele	 G	 A	 T	 G	 A	 A	 A	 A	 C	 T	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Effect	allele	frequency	 0.35	 0.52	 0.83	 0.17	 0.87	 0.80	 0.25	 0.14	 0.16	 0.76	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Betai	 0.086	 0.085	 0.103	 0.058	 0.041	 0.048	 0.064	 0.142	 0.065	 0.100	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Base	pairsj	 103.2	 102.0	 123.6	 69.6	 49.2	 57.6	 76.8	 170.4	 78.0	 120.0	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Subject1	 G/G	 C/A	 C/C	 G/G	 T/T	 A/A	 A/A	 A/A	 C/C	 C/T	 10	 0	 1	 2	 0	 2	 0	 0	 0	 0	 1	 6	 0.60	 0	 102.0	 247.2	 0	 98.4	 0	 0	 0	 0	 120.0	 567.6	 56.76	
Subject2	 G/G	 C/A	 C/C	 G/G	 T/T	 G/G	 A/A	 A/A	 C/C	 C/C	 10	 0	 1	 2	 0	 2	 2	 0	 0	 0	 2	 9	 0.90	 0	 102.0	 247.2	 0	 98.4	 115.2	 0	 0	 0	 240.0	 802.8	 80.28	
Subject3	 C/C	 C/A	 C/T	 G/G	 T/T	 G/A	 G/G	 A/A	 C/C	 C/C	 10	 2	 1	 1	 0	 2	 1	 2	 0	 0	 2	 11	 1.10	 206.4	 102.0	 123.6	 0	 98.4	 57.6	 153.6	 0	 0	 240.0	 981.6	 98.16	
Subject4	 G/G	 C/C	 C/C	 G/G	 T/T	 G/G	 A/G	 A/A	 C/C	 C/C	 10	 0	 2	 2	 0	 2	 2	 1	 0	 0	 2	 11	 1.10	 0	 204.0	 247.2	 0	 98.4	 115.2	 76.8	 0	 0	 240.0	 981.6	 98.16	
Subject5	 G/G	 C/A	 C/C	 G/G	 T/T	 A/A	 A/A	 A/A	 C/C	 C/T	 10	 0	 1	 2	 0	 2	 0	 0	 0	 0	 1	 6	 0.60	 0	 102.0	 247.2	 0	 98.4	 0	 0	 0	 0	 120.0	 567.6	 56.76	
Subject6	 C/C	 C/C	 C/T	 G/G	 T/T	 G/G	 G/G	 C/C	 C/A	 C/T	 10	 2	 2	 1	 0	 2	 2	 2	 2	 1	 1	 15	 1.50	 206.4	 204.0	 123.6	 0	 98.4	 115.2	 153.6	 340.8	 78.0	 120.0	 1440.0	 144	
Subject7	 G/C	 C/A	 C/C	 G/G	 T/T	 G/A	 A/A	 A/A	 C/C	 C/C	 10	 1	 1	 2	 0	 2	 1	 0	 0	 0	 2	 9	 0.90	 103.2	 102.0	 247.2	 0	 98.4	 57.6	 0	 0	 0	 240.0	 848.4	 84.84	
Subject8	 G/G	 C/A	 C/C	 G/G	 T/T	 G/G	 A/A	 A/C	 C/C	 C/C	 10	 0	 1	 2	 0	 2	 2	 0	 1	 0	 2	 10	 1.00	 0	 102.0	 247.2	 0	 98.4	 115.2	 0	 170.4	 0	 240.0	 973.2	 97.32	
Subject9	 -	 C/A	 C/T	 G/G	 T/T	 G/G	 A/G	 A/C	 C/C	 C/T	 9	 -	 1	 1	 0	 2	 2	 1	 1	 0	 1	 9	 1.00	 	 102.0	 123.6	 0	 98.4	 115.2	 76.8	 170.4	 0	 120.0	 806.4	 89.6	
Subject10	 -	 C/A	 C/T	 G/G	 T/T	 G/G	 A/A	 A/A	 C/C	 C/C	 9	 -	 1	 1	 0	 2	 2	 0	 0	 0	 2	 8	 0.89	 	 102.0	 123.6	 0	 98.4	 115.2	 0	 0	 0	 240.0	 679.2	 75.47	
aFor	each	SNP	and	each	subject,	the	number	of	effect	alleles	in	the	genotype	is	counted.	
bFor	each	SNP	and	each	subject,	the	number	of	effect	alleles	in	the	genotype	is	multiplied	by	the	base	pairs	associated	with	the	effect	allele	of	each	SNP.	
cSurrogate	of	rs412658	(r2=1).	
dUnweighted	score	for	the	subject:	sum	of	the	scores	of	each	SNPs.	
eAverage	unweighted	score	for	the	subject:	average	of	the	scores	of	each	SNPs.	
fWeighted	score	for	the	subject:	sum	of	the	scores	of	each	SNPs.	
gAverage	weighted	score	for	the	subject:	average	of	the	scores	of	each	SNPs.	
hAllele	associated	with	longer	telomeres.	
iBeta	coefficients	for	association	of	each	SNP	with	telomere	length,	providing	an	estimate	of	the	relative	importance	of	each	SNP.	
jEstimates	of	the	per-allele	effect	on	LTL	in	base	pairs,	following	ref.	52.	
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Supplementary	table	2.	Data	on	known	risk	factors	for	pancreatic	cancer.	
	 PDAC	cases	 Controls	
Tobacco	smoking	
Ever	smoker	 260	 210	
Never	smoker	 558	 1,300	
Total	 818	 1,510	
	 	 	
Diabetes	diagnosed	before	onset	of	pancreatic	cancer	
Yes	 115	 603	
No	 173	 1,434	
Total	 288	 2,037	
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Supplementary	table	3.	Literature	review	on	telomere	length	and	PDAC	risk.	
Study	 Measurement	type	 Cases/controls	 Study	type	 Effect	observed	 Ethnicity	 Reference	in	
the	manuscript	
Skinner	et.	al	2012	 Real-time	PCR	 499/963	 Retrospective	 Short	telomeres	increase	risk	 European-Americans	 27	
Lynch	et.al,	2013	 Real-time	PCR	 193/660	 Prospective	cohort	 Long	telomeres	increase	risk	 Finnish	 26	
Campa	et	al,	2014	 Real-time	PCR	 331/331	 Prospective	cohort	 U-shaped	 Europeans	 28	
Zhang	et.	Al,	2016	 Real-time	PCR	 900/900	 Prospective	cohort	 U-shaped	 Chinese	 29	
Bao	et	al.	2016	 Real-time	PCR	 386/896		 Prospective	cohort	 Short	telomeres	increase	risk	 European-Americans	 5	
	
	
